Clinical trials
Phase 2 Leukemia trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
24 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 19 |
| Recruiting | 3 |
| Terminated | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 5 |
| Bristol-Myers Squibb | 3 |
| Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias | 3 |
| Amgen Research (Munich) GmbH | 2 |
| Pfizer | 2 |
| Cogent Biosciences, Inc. | 1 |
| Daiichi Sankyo | 1 |
| Fundació Sant Joan de Déu | 1 |
| Fundación Teófilo Hernando, Spain | 1 |
| GlaxoSmithKline | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia | 24 |
| Leukemia, Myeloid, Acute | 8 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 6 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 |
| Bronchiolitis Obliterans Syndrome | 4 |
| Hematologic Diseases | 4 |
| Leukemia, Myeloid | 4 |
| Myeloproliferative Disorders | 3 |
| Neoplasms | 3 |
| Bone Marrow Diseases | 2 |
Trials
Showing 1 to 24 of 24. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.